MIRA
INFORM REPORT
|
Report Date : |
30.08.2007 |
IDENTIFICATION DETAILS
|
Name : |
ALCHEM INTERNATIONAL LIMITED |
|
|
|
|
Registered Office : |
301, Avalon Apartments, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2006 |
|
|
|
|
Date of Incorporation : |
03.04.1982 |
|
|
|
|
Com. Reg. No.: |
55-13415 |
|
|
|
|
CIN No.: [Company
Identification No.] |
L74899DL1982PLC013415 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
DELA03276A |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAACA2251L |
|
|
|
|
Legal Form : |
Closely Held Public Limited Liability Company. |
|
|
|
|
Line of Business : |
Manufacturing and Marketing of Pharmaceuticals, Medical Chemicals, Botanical Products, Bulk Drugs and Drug Intermediates Extracts. |
RATING & COMMENTS
|
MIRA’s Rating : |
Aa |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
Maximum Credit Limit : |
USD 1600000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well – established and reputed company having fine track. Trade relations are fair. Financial position is good. Payments are correct and as per commitments. The company can be considered good for any normal business dealings at usual trade terms and conditions. It can be regarded as a promising business partner in a medium to long – run |
LOCATIONS
|
Registered Office / Head Office : |
301, Avalon Apartments, |
|
Tel. No.: |
91-11-26808420 |
|
Fax No. : |
91-11-26801170 |
|
E-Mail : |
alchem.intl@elnet.ems.vsnl.net.in raman.mehta@elnet.ems.vsnl.net.in |
|
Website : |
|
|
Area : |
2700 sq. ft. |
|
Location : |
Owned |
|
|
|
|
Factory : |
25/2, |
|
Tel. No.: |
91-129-25232356/25234008/25233335 |
|
Fax No.: |
91-129-25230192 |
|
Area : |
12 hectors |
|
Location : |
Owned |
DIRECTORS
|
Name : |
Mr. Prabir Sen Gupta |
|
Designation : |
Managing Director |
|
Address : |
House No. 3294, Sector 3, Ballabgarh, |
|
Date of Birth/Age : |
15.10.1957 |
|
Date of Appointment : |
21.06.1989 |
|
|
|
|
Name : |
Mr. Ramesh Kumar Mehta |
|
Designation : |
Director |
|
Address : |
25/2, |
|
Date of Birth/Age : |
20.06.1954 |
|
Date of Appointment : |
01.04.1992 |
|
|
|
|
Name : |
Mr. Mahendra Kumar Bali |
|
Designation : |
Director |
|
Address : |
A-2, 240, Janakpuri, |
|
Date of Birth/Age : |
18.09.1940 |
|
Date of Appointment : |
29.09.2001 |
KEY EXECUTIVES
|
Name : |
Ajay K. Goyal and Company |
|
Designation : |
Company Secretary |
|
Address : |
313, Vardhman Capital Mall, Gulabi Bagh, |
|
Mobile No. : |
91-9810398621 |
|
E-mail : |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
|
Names of Shareholders |
|
No. of Shares |
|
Mr. Raman Mehta |
|
26,415 |
|
Mrs. Nidhi Mehta |
|
3,260 |
|
Mr. Bharat Mehta |
|
1,815 |
|
Ms. Neha Mehta |
|
1,750 |
|
Mrs. Divya Mehta |
|
1,750 |
|
Raman Mehta (HUF) |
|
5 |
|
Nidhi Mehta Family |
|
5 |
|
Total |
|
35,000 |
|
|
|
|
|
Equity Share
Breakup |
|
|
|
Category |
|
Percentage of
Holding |
|
Other top fifty shareholders |
|
100.00 % |
BUSINESS DETAILS
|
Line of Business : |
Manufacturing and Marketing of Pharmaceuticals, Medical Chemicals, Botanical Products, Bulk Drugs and Drug Intermediates Extracts. |
|
|
|
|
Products : |
· Natural Pharmaceuticals & other Active Ingredients · Ayurvedic Extracts & Health Food · Oleoresins · Standardized Extracts · Natural Cosmetics Ingredients |
|
|
|
|
Exports : |
|
|
Countries : |
|
|
|
|
|
Imports : |
|
|
Countries : |
|
|
|
|
|
Terms : |
|
|
Selling : |
D/A, Credit (90 to 120 days) or D/P |
|
|
|
|
Purchasing : |
D/A or Credit (90 to 120 days) |
GENERAL INFORMATION
|
Customers : |
Ø
Ø
Pharmacare Limited, Ø
Slalter & Frith Limited, Ø
Deg Import Company, Ø
Actips International Pearling Trading, |
|
|
|
|
No. of Employees : |
Around 50 |
|
|
|
|
Bankers : |
Overseas Branch,
Jawahar Vyapar Bhawan, 1, Tolstoy Marg,
|
|
|
|
|
Banking
Relations : |
Satisfactory |
|
|
|
|
Auditors : |
|
|
Name : |
Jain Chopra & Company Chartered Accountants |
|
Address : |
105, Jyoti Bhavan, Commercial Complex, Mukherjee Nagar, |
|
Tel. No.: |
91-11-27652776/27652091 |
|
Fax No.: |
91-11-27650155 |
|
E-Mail : |
|
|
|
|
|
Associates : |
Lepro Herbals Private Limited Twin Multiflora |
|
|
|
|
Subsidiaries : |
Alchem International (HK) Limited |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
50,000 |
Equity Shares |
Rs.100/- each |
Rs. 5.000 millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
35,000 |
Equity Shares |
Rs.100/- each |
Rs. 3.500 millions |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES
OF FUNDS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
3.500 |
3.500 |
3.500 |
|
|
3] Reserves & Surplus |
412.685 |
400.034 |
364.434 |
|
NETWORTH
|
416.185 |
403.534 |
367.934 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
290.654 |
294.951 |
266.773 |
|
|
2] Unsecured Loans |
60.452 |
67.133 |
83.274 |
|
TOTAL BORROWING
|
351.106 |
362.084 |
350.047 |
|
|
DEFERRED TAX LIABILITIES |
2.400 |
9.649 |
9.400 |
|
|
|
|
|
|
|
TOTAL
|
769.691 |
775.267 |
727.381 |
|
|
|
|
|
|
|
APPLICATION OF FUNDS
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block]
|
251.232 |
263.168 |
243.330 |
|
Capital work-in-progress
|
2.012 |
4.153 |
13.662 |
|
|
Advance against fixed assets |
0.000 |
14.881 |
13.717 |
|
|
|
|
|
|
|
INVESTMENT
|
0.498 |
0.498 |
0.498 |
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS &
ADVANCES
|
|
|
|
|
|
|
Inventories
|
545.733 |
515.313 |
426.301 |
|
|
Sundry Debtors
|
175.387 |
237.170 |
161.377 |
|
|
Cash & Bank Balances
|
11.066 |
29.075 |
17.152 |
|
|
Other Current Assets
|
6.659 |
0.000 |
0.000 |
|
|
Loans & Advances
|
49.956 |
46.398 |
37.725 |
Total Current Assets
|
788.801 |
827.956 |
642.555 |
|
Less :
CURRENT LIABILITIES & PROVISIONS
|
|
|
|
|
|
|
Current Liabilities
|
258.426 |
312.640 |
168.201 |
|
|
Provisions
|
14.426 |
22.749 |
18.180 |
Total Current Liabilities
|
272.852
|
335.389
|
186.381
|
|
Net Current Assets
|
515.949 |
492.567 |
456.174 |
|
|
|
|
|
|
|
TOTAL
|
769.691 |
775.267 |
727.381 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
|
Sales Turnover |
819.321 |
839.783 |
788.582 |
|
|
Other Income |
4.208 |
5.575 |
|
|
|
Total Income |
823.529 |
845.358 |
788.582 |
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
806.714 |
791.253 |
51.593 |
|
|
Provision for Taxation |
16.815 |
54.105 |
16.412 |
|
|
Profit/(Loss) After Tax |
789.899 |
737.148 |
35.181 |
|
|
|
|
|
|
|
|
Earnings in Foreign Currency : |
|
|
|
|
|
|
Export Earnings |
510.743 |
612.834 |
|
|
|
Other Earnings |
596.666 |
632.227 |
|
|
Total Earnings |
1107.409 |
1245.061 |
612.834 |
|
|
|
|
|
|
|
|
Imports : |
|
|
|
|
|
|
Raw Materials |
249.877 |
159.829 |
|
|
|
Capital Goods |
1.639 |
10.449 |
|
|
Total Imports |
251.516 |
170.278 |
170.278 |
|
|
|
|
|
|
|
|
Expenditures : |
|
|
|
|
|
|
Raw Material Consumed |
497.197 |
482.003 |
|
|
|
Salaries, Wages, Bonus, etc. |
18.700 |
17.202 |
|
|
|
Managerial Remuneration |
0.120 |
0.567 |
|
|
|
Payment to Auditors |
0.345 |
0.307 |
655.554 |
|
|
Interest |
31.962 |
28.323 |
|
|
|
Insurance Expenses |
5.540 |
5.826 |
|
|
|
Power & Fuel |
56.710 |
60.749 |
|
|
|
Depreciation |
53.544 |
55.541 |
|
|
|
Other Expenditure |
142.596 |
140.735 |
|
|
Total Expenditure |
806.714 |
791.253 |
655.554 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
PAT / Total Income |
(%) |
95.92
|
87.20 |
4.46 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
98.46
|
94.22 |
6.59 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
77.57
|
72.52 |
5.65 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
1.94
|
1.96 |
0.14 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
1.50
|
1.73 |
1.46 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.89
|
2.47 |
3.45 |
LOCAL AGENCY FURTHER INFORMATION
Registered office the company has been shifted from 201,
Business :
Subject is engaged in manufacturing of Drugs, Drugs Intermediate Extracts, Alkaloids, Natural Pharmaceuticals, Oleoresins, Standardized Extracts, Ayurvedic Extracts, Health Food and Natural Cosmetics Ingredients.
It is specializing in alkaloids and standardized herbal extracts, manufactured as per GMP and the final products are standardized by usage of the latest analytical techniques, like HPCL, NMR, GLC etc.
Fixed Assets
- Land
- Lab Apparatus
- Computer Accessories
- Road Development
- Electrical Fittings and Equipments
- Machinery and Equipments
- Air Conditioner
- Vehicles
- Office Equipments
- Pollution Treatment Plant
Form 8 Particular for creation or
modification of charges
|
Corporation identity number or foreign company registrations number of the company |
L74899DL1982PLC013415 |
|
Name of the company |
ALCHEM INTERNATIONAL LIMITED |
|
Address |
201, |
|
This Form is for |
Modification Charge |
|
Particular of the charge holder |
State Bank of |
|
Amount Secure by the charge |
Rs. 125.000 Millions |
|
Description of the property charge whether it is a charge on |
Immovable, Stock in trade, Book Debts and other |
|
Modification charge Charge identification number of the charge to be modified |
80000449 |
|
Date of instrument modifying the charge |
21.07.2006 |
|
Particulars of the present modification |
EM of unit No. 201, 203, 205, 207, 209, 211, 213, 215 at 201 Empire Plaza, M G Road, Sultanpur, New Delhi to secure WCF from Citibank – Rs. 80.000 Millions, State Bank of India – Rs. 154.000 Millions, ABN Bank – Rs. 60.000 Millions |
|
Name of the company |
ALCHEM INTERNATIONAL LIMITED |
|
Presented By |
Mr. M K Bali |
|
1) Date and description of instrument creating the change |
Agreement of loan for overall limit dated 30.12.2003 Regd. On – 16.02.2004 Agreement of hypothecation of goods and assets dated 30.12.2003 Letter regarding the grant of individual limits within the overall limit dated 30.12.2003 |
|
2) Amount secured by the charge/amount owing on the securities of charge |
C. C. – Rs. 50.000 Millions EPC/FBP – Rs. 70.000 Millions Total FBL – Rs. 120.000 Millions LC (Domestic/Foreign) – Rs. 5.000 Millions (With 100% interchangeability between L/C and BG) Total NFB – Rs. 5.000 Millions Grand Total – Rs. 125.000 Millions |
|
3) Short particular of the property charged. If the property acquired is subject to charge, date of the acquired of the property should be given |
Primary – CC (Hypothecation/EPC/FBP/LC : Hypothcation of stocks and receivable including present and future both Collateral Pari Passu charge with other members banks, on fixed assets of the company excluding those which are specifically charged to Citi Bank having residue value of Rs. 1400.000 Millions as on 31.03.2003 In addition, pari passu charge following immovable properties along with ABN Amro Bank and Citibank 4, Empire Estate, 502, Empire Apartment, Flat No. 301, Avion Apartment, Mangalapuri Mahrauli, Flat No. 303, Avion Apartment, Mangalapuri Mahrauli, 3, Empire Estate, Factory land and building, consisting of area of 29.70 acres located at NH – 2, Ballabhgarh in the name of arpee corporation |
|
4) Gist of the terms and conditions and extent and operation of the charge. |
EPC (upto 180 days) – Interest as per RBI/SBI directive subject to change regarding export finance Cash Credit (Hypothecation) – Interest as applicable to SB – 2 rating presently 1.50% above SBAR minimum 12.00% applied at monthly rests Margin – Drawings under EPC will be permitted to the maximum extent of LC or firm export order subject to availability drawing power against stock held by the company Margins Inventors shall be 25% Domestic receivable shall be 25% Export receivable shall be |
|
5) Name and Address and description of the person entitled to the charge. |
State Bank of |
|
6) Date and brief description of instrument modifying the charge |
Supplementary agreement of lan for increased in the overall limit dated 02.05.2005 Supplementary deed of grantee for increased in overall limit dated 02.05.2005 Letter regarding the grant of individual limit with in the overall limit dated 02.05.2005 Letter for NOC from ABN Bank bearing no. CA/05/1388 dated 24.09.2005 |
|
7) Particulars of modifications specifying the terms and conditions or the extent of operations of the charge in which modification is made and the details of the modification. |
C.C. – Existing – Rs. 50.000 Millions, Revised Limit – Rs. 50.000 Millions EOC/FBP – Rs. 70.000 Millions, Revised Limit – Rs. 70.000 Millions SLC - Rs. 0.000 Millions, Revised Limit – Rs. 24.000 Millions LC - Rs. 5.000 Millions, Revised Limit – Rs. 5.000 Millions Total NFB - Rs. 5.000 Millions, Revised Limit – Rs. 5.000 Millions Total - Rs. 125.000 Millions, Revised Limit – Rs. 149.000 Millions Term Loan - Rs. 40.000 Millions, Revised Limit – Rs. 40.000 Millions Primary – CC (Hypothecation/EPC/FBP/LC Pari Passu charge on current assets of the company including present and future Collateral Pari Passu charge with other members banks, on fixed assets of the company excluding those which are specifically charged to Citi Bank |
|
This form is for |
Modification of
charge |
|
Charge
identification number of the charge to be modified |
80000449 |
|
Corporate identity
number of the company |
L74899DL1982PLC013415 |
|
Name of the
company |
ALCHEM INTERNATIONAL LIMITED |
|
Address of the
registered office or of the principal place of business in |
201, |
|
Type of charge |
Immovable
Property Movable Property Book Debts |
|
Particular of
charge holder |
State Bank of |
|
Nature of
description of the instrument creating or modifying the charge |
|
|
Date of
instrument Creating the charge |
09.02.2007 |
|
Amount secured by
the charge |
Rs. 242.700
Millions |
|
Brief particulars
of the principal terms an conditions and extent and operation of the charge |
Rate of interest EPC – Up to 180 days
: @ 2.90 % below SBAR [11.50%], Minimum 8.60 % p.a. at monthly rests, up to
181-270 days; @ 1.65 % BELOW SBAR [11.50 % ] minimum 9.85 % p.a. at monthly
rests. FBP / FBD as per SBI Exporter’s Gold Card Scheme. Cash Credit /
Corporate Loan : At SBAR minimum 11.50 % p.a. with monthly rests subject to
change from time to time LC / BG as per bank rules Stand by Line of Credit
Stand by limit under SBI Exporter’s Gold Card Scheme : As per SBI Exporter’s
Gold Card Scheme. Terms of
repayment : New Corporate
Loan : Repayable in 32 equal monthly installments of Rs. 1.060 Millions each
and 33rd installments of Rs. 1.080 Millions beginning from
01.04.2007 Margin Margin : Raw
Materials Stock in Process, Finished Goods, packing Materials, Book debts
receivables – 25 % Bank Guarantee / LC 10 % Extent and
operation of the charge : Extent and
operation of the charge : 100 % Others : The above is to
secure the working capital facilities of Rs. 242.700 Millions |
|
Short particulars
of the property charged |
|
|
Date of latest
modification prior to the present modification |
23.02.2006 |
|
Particulars of
the present modification |
The extent of
operation of the charge on current as well as fixed assets for securing
working capital / corporate loan facilities stands enhanced due to increase in
overall limits form Rs. 210.500 Millions to Rs. 242.700 Millions Terms and
conditions as per agreements letter no. SBI/OBND/RM-III/2006-07/334 dated
22.01.2007 |
Profile :
Alchem is the largest phytochemical plant in the country with an extraction capacity of 8000 tonnes per annum and spread over 34 acres.
The growth has been remarkable (four fold in five years)….the customer base spans 31 countries and covers over 200 customers.
Alchem International Limited has the benefit of 60 years of three generations of rich and dedicated family experience, who have down- the- years, imparted in-depth and researched knowledge to the present incumbents who now the guide the growing fortunes of the Company.
Product quality is achieved through a constant interface with various controls which are rigidly enforced and constantly monitored.
The company ensures the implementation of good manufacturing practices (GMP)
Other Group companies:
Ø Lepro Herbal Private Limited, for the manufacture of standardized extracts
Ø Twin Multiflora ,for the cultivation of medicinal plants and promote floriculture.
Ø Alchem II, over a 20 acre spread a state of art factory in the pipeline to cater to its growing customer requirements
For half a century they are sourcing some of the most quality-critical and rare medicinal plants. That experience enable to meet any requirement, sourcing raw material with precisely the right active components and to extract product from them to tight specification : after all 95% of alkaloids and extracts are exported to Japan, Western Europe and USA.
The large plant area helps, too, by permitting physical separation of extractor units and ensuring product purity. A large range of extractors, from 2,000 litres to 15,000 litres mans can process small or large batches without delay.
The company has over 50 years of experience behind it and has an extraction capacity of more than 4000 tons of various herbs per year and welcomes development of new products on an exclusive confidential basis from overseas clients. The extraction capacity is divided into seven separate extraction plants which are physically separated from each other by over 15 metres so that product purity is maintained, while seven different products are being processed.
The company also has a 150 ton / per annum Pilot Plant where experimental trials can be conducted on extraction and purification of different herbs for exclusive use of collaborators.
As testimony of the company’s strong quality control, over
95% of its production was exported to
Alchem International Limited is exclusively dedicated to the manufacture of phyto-chemicals for medicinal and cosmetic use. Technological capability and prowess ensures extraction of an isolated active molecule from a biomass of extract.
For end-to end need for bulk drugs, they would be a one-stop shop for
pharmaceutical ingredients, cosmetic, Nutraceutical, standardized and
synergized extracts.
Alchem's corporate endeavor has always been to know the product and build
manufacturing processes around it. These could be proprietary or customized.
It prides itself in product quality and continuous ongoing research R& D is
the company's committed focus and philosophy.
The growing needs of the market are assessed, calibrated and addressed through
continuous participation in trade shows.
The Alchem facility expands over an area of 34 acres with 6 isolated plants having a total extraction capacity of over 8000 tons per year.
Most products have dedicated purification facilities and a class 100,000 room is maintained for APIs.
These facilities are GMP and cGMP certified and have been audited by internationally reputed companies.
They have a dedicated RandD for process development which is complemented by a pilot plant that can process 600 kgs of biomass for scaling up production.
Production facilities are supported with: latest machinery for extraction, purification, Spray drying, jet-mailing and packing facilities for powder API's and extracts
Full electricity back up, Effluent treatment plant, air and water treatment units are commissioned to ensure an eco-friendly environment
Products
Natural Pharmaceuticals and Other Ingredients
v Alpisarin U.S.S.R.P. (Herpies)
v Androgrpholide
v Belladonna Total Alkaloids
v Berberine Hydrochloride IP
v Berberine Tannate JP
v Camptothecin
v Podophyllotoxin
v Podophyllum Resin BP
v Quinine Sulphate and HCL
v Raubasine
v Silymarine
v Thiocolchicoside
v Yohimbine HCL
v Xanthotoxin (Methoxsalen)
Oleoresins
v Oleoresins Capsicum
v Oleoresins Tuemeric
Standardized Extracts
v Belladonna Leaf Extract BP/NF
v Boswellia Serrata Extract
v Capsicum Oleresin
v Centella Asiatica Extract
v Creteva Extract
v Curcumin
v Green Tea Extract
v Guggulipids
v Horse Chestnut Extract
v Kava Kava Extract
v Lycopene Extract
v Passiflora Extract
v Piperine
v Scopolia Extract
v Saw Palmetto Extract
v (Serenoa Repens)
v
v Valerian Officinalis Extract
v Yohimbine Extract (1 to 8%)
Natural Cosmetics Ingredients
v Alpisarin
v Andrographolides
v 18 Beta Glycyrrhetinic Acid
v Boswellia Extract
v Centella Asiatica
v Forskohlin
v Pygenum Extract
v Tetra
Hydro Curcumin (THC)
Ayurvedic Extracts and Health Food
v Ashwagandha Extract
v Boswellia Serrata Extract
v Catechu Extract
v Guggul Extract
v Syngergized Extract
v Tulsi Extract
v Vasaka
Extract
It is in trade terms with :-
Ø Parling Trading Company, Hongkong
Ø
K.L. & J.D. Hansen Private Limited,
Ø
Ø
World
Ø
Sarveshwar Udyog, Bhuj,
Ø
Durga Enterprises, Bhuj,
Active
Pharmaceuticals
Alpisarin U.S.S.R.P (Herpes)
Artesunate
Artemisinin
Artemether
Arteether
Camptothecin
Colchicine (BP/EP/USP)
Coenzyme Q- 10 (CO-Q 10)
10-DAB
(De-Acetyl–Baccatin)
Digoxin (BP/EP/JP/USP)
Enoxolone
Forskohlin
18-Beta Glycyrrhetinic Acid
Hyoscine Hydrobromide BP
Hyoscine N Butyl Bromide (BP/EP)
Hyoscyamine and Salts
Glycyrrhizinate Ammonium (MAG)
Nicotine (USP)
Nicotine Tartarate
Noscapine (BP/EP/USP)
Paclitaxel
Piperine
Podophyllum Resin BP
Quinine Sulphate
Quinine HCL and DiHCL
Quinidine Sulphate and HCL
Reserpine BP/USP
Sennosides (10 to 100%)
Thiocolchicoside
Yohimbine HCL USP
Xanthotoxin USP (Methoxsalen)
Nutracuticals Extracts
Belladonna Leaf Extract (BP/NF)
Boswellia Serrat Extract(65% and 95%) Capsicum Oleoresin
Centella Asiatica Extract
Coleus Forskohlin Extract (10 to 100%)
Curcumin (95%)
Devil’s Claw Extract (Harpagophytum)
Echinacea Extract
Garcinia Extract (Water Soluble and Spray Dried)
Garcinia Extract (50 to 65%)
Ginger Extract
Griffonia Extract (20% 5-HTP)
Gymnema Sylvestre Extract
Horse Chestnut Extract
Humulus Lupulus Extract
Java Tea Extract (Orthosiphon)
Passiflora Extract
Scopolia Extract
Senna Extract (BPC/NF)
Solanesol (min95%) (Intermediate CoQ
Valerian Officinalis Extract
Yohimbe Extract (1 to 10%)
Cosmetics Ingredients
Alpisarin (Mangiferin)
Andrographolides
Apigenin
18 Beta Glycyrrhetinic Acid
Boswellia Extract
Cafestol
Centella Asiatica
Forskohlin
Glabridin 20-60%
Kahweol
Pygeum Extract
Resveratrol
Tetra Hydro Curcumin (THC)
Ayuervedic Extracts
Diabetes
Rheumatic(Arthritis
Obesity(Weight management
Memory, Stress and
Concentration
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.41.04 |
|
|
1 |
Rs.82.76 |
|
Euro |
1 |
Rs.56.07 |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
8 |
|
PAID-UP CAPITAL |
1~10 |
8 |
|
OPERATING SCALE |
1~10 |
8 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
8 |
|
--PROFITABILIRY |
1~10 |
8 |
|
--LIQUIDITY |
1~10 |
8 |
|
--LEVERAGE |
1~10 |
8 |
|
--RESERVES |
1~10 |
8 |
|
--CREDIT LINES |
1~10 |
8 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
72 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|